Ensysce Biosciences, Inc.
No SEC Form 4 filings for $ENSC in the last 30 days.
Ensysce Biosciences (NASDAQ:ENSC) reported a sharp rise in short interest: 814,605 shares as of May 15, up from 52,730 on April 30, with about 5.7% of shares sold short and a days-to-cover ratio of 0.1 (based on average daily volume). The stock traded at $0.30. The company reported May 15 quarterly EPS of -$0.52 and revenue of $0.96M.
Ensysce Biosciences reported a Q4 net loss of $2.8 million, showing a narrowing compared to previous periods. This financial update indicates a positive trend for the company's fiscal performance. The information was provided by Reuters and cited by TradingView News.
Ensysce Biosciences ( NASDAQ:ENSC ) , a biotechnology company developing abuse-deterrent opioid therapies, reported its second-quarter results on August 13, 2025. The quarter's biggest news included the launch of a pivotal Phase 3 clinical trial for its lead program, PF614, and full enrollment in ...
